US Bancorp
CSTL icon

US Bancorp’s Castle Biosciences CSTL Stock Holding History

US Bancorp’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
4,478
+4,386
+4,767% +$97.7K ﹤0.01% 2415
2026
Q1 		$2.26K Buy
92
+44
+92% +$1.44K ﹤0.01% 3776
2025
Q4 		$1.87K Buy
48
+22
+85% +$709 ﹤0.01% 3770
2025
Q3 		$592 Buy
+26
New +$528 ﹤0.01% 3860
2025
Q2 		– Sell
-24
Closed -$480 – 4189
2025
Q1 		$480 Sell
24
-1,178
-98% -$29.2K ﹤0.01% 4045
2024
Q4 		$32K Sell
1,202
-3,413
-74% -$104K ﹤0.01% 2951
2024
Q3 		$132K Buy
4,615
+4,383
+1,889% +$112K ﹤0.01% 2253
2024
Q2 		$5.05K Sell
232
-234
-50% -$5.21K ﹤0.01% 3510
2024
Q1 		$10.3K Buy
466
+165
+55% +$3.59K ﹤0.01% 3328
2023
Q4 		$6.5K Buy
301
+23
+8% +$405 ﹤0.01% 3451
2023
Q3 		$4.7K Sell
278
-1
-0.4% -$17 ﹤0.01% 3448
2023
Q2 		$3.83K Buy
279
+40
+17% +$811 ﹤0.01% 3551
2023
Q1 		$5.43K Buy
239
+19
+9% +$464 ﹤0.01% 3497
2022
Q4 		$5.18K Sell
220
-3,363
-94% -$78K ﹤0.01% 3501
2022
Q3 		$93K Sell
3,583
-9,224
-72% -$259K ﹤0.01% 2226
2022
Q2 		$281K Sell
12,807
-3,661
-22% -$85.1K ﹤0.01% 1729
2022
Q1 		$739K Buy
16,468
+3,694
+29% +$153K ﹤0.01% 1326
2021
Q4 		$547K Sell
12,774
-816
-6% -$42.6K ﹤0.01% 1481
2021
Q3 		$904K Buy
13,590
+10,151
+295% +$714K ﹤0.01% 1234
2021
Q2 		$252K Buy
3,439
+2,829
+464% +$187K ﹤0.01% 1873
2021
Q1 		$42K Buy
+610
New +$45.8K ﹤0.01% 2662

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's CSTL Position: Q2 2026 in Review

US Bancorp increased its Castle Biosciences (CSTL) stake by 4,767% in Q2 2026, buying an estimated $97.7K and bringing the position to 4,478 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

US Bancorp first reported a position in CSTL in Q1 2021 and has held it in 21 quarters since. The position peaked at $904K in Q3 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • US Bancorp held 4,478 shares of Castle Biosciences worth $107K as of Q2 2026.
  • US Bancorp bought 4,386 Castle Biosciences shares in Q2 2026, an estimated $97.7K.
  • Castle Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2415 holding.
  • US Bancorp first reported a position in Castle Biosciences in Q1 2021 and has held it in 21 quarters since.
  • US Bancorp's Castle Biosciences position peaked at $904K in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.